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Macrophages transformed foam cell formation occurs as a result of leukocyte accumulation
mediated through intercellular adhesion molecule 1 (ICAM1), vascular cell adhesion mole-
cule 1 (VCAM1), and E-selectin, secreted by inflamed or damaged endothelium. The key
molecule is the ICAM-1,member of the adhesion immunoglobulin super family thatmaps to
chromosome 19 p13.2-p13.3 codes for 505 amino acids have five extracellular domains
including circulatory leukocytes binding site (primarily monocytes) for recruiting it at the
sites of inflammation and the tight adhesion with vascular endothelium for the above
mentioned pathogenesis as an initial step. Hence the objective of the current paper is to
review the Genome Wide Association (GWA) studies and summarizes its understanding of
functional Single Nucleotide Polymorphism (SNP's) of ICAM-1 clinical association to provide
better guidance for the clinicians and researchers of the merits, demerits of the current re-
sults and direct them to do research on larger number of population for better prospective.
Copyright © 2015, Cardiological Society of India. All rights reserved.1. Introduction
Endothelium remodeling is a cardinal process for the cause of
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teins and other plasma components that increases the adhe-
sive capacity with up-regulated leukocyte adhesionmolecules
(L-selectin, integrins, and platelet endothelial-cell adhesion
molecule 1 (PECAM-1)) and endothelial adhesion molecules
(including E-selectin, P-selectin, endothelial intercellular
adhesion molecule-1 (ICAM-1), vascular cellular adhesion
molecule (VCAM-1)). The keymolecule is the ICAM-1,member
of the adhesion immunolglobulin superfamily9,10 thatmaps to
chromosome 19 p13.2-p13.3 codes for 505 amino acids possess
5 extracellular domains including circulatory leukocytes
binding site (primarily monocytes) for recruiting it at the sites
of inflammation and the tight adhesion with vascular endo-
thelium for the above mentioned pathogenesis as an initial
step. Epidemiological studies are reported from various parts
of the world but still the results are controversial11,12 and
inconclusive.13,14 Hence the objective of the current paper is to
review the Genome Wide Association (GWA) studies and
summarizes its understanding of functional Single Nucleotide
Polymorphism (SNP's) of ICAM-1 clinical association to pro-
vide better guidance for the clinicians and researchers of the
merits, demerits of the current results and direct them to
perform research on larger number of population for better
prospective.2. Cell adhesion molecular family (CAM)
Selectin family (E, P and L-selectin), immunoglobulin super
family (ICAM, PECAM-1 and VCAM-1) and integrins (CD11/18)
belongs to CAM that helps the cells interactions. The rapid
cycle of attachment, detachment and reattachment underly-
ing rolling of leukocyte through the glycoprotein and glyco-
lipids containing sialyl-Lewisx (sLex, CD 15s) structure11 is
found on neutrophils, monocytes, and some lymphocytes that
interact with selectins. They are clustered in tandem within a
220-kb region of chromosome 1q23.12 Activated endothe-
lium13 transiently expresses E-selectin (ELAM-1, SELE, CD62E)
which supports rolling of neutrophils, monocytes, eosino-
phils, and some lymphocytes.
There are five members14 of ICAM immunoglobulin super
family. Human ICAM-1 gene posses 7 exons and 6 introns
making a total of 15.5 kb size in which protein coding region is
of 3.3e3.5 kb. ICAM-1 gene structure and its up regulation
process at the transcriptional and its post transcriptional have
been reported more than a decade before.15 Its regulation is
governed bymajor pathways for the activation of sICAM-1 are
NF-kB (TNF-a, IL-1b) and Janus kinases (JAK)-signal trans-
ducers signal transduction (STAT) (IFN-g) pathway through
cis-elements in proximal NF-kB binding site and IFN-g
responsive element (IRE) located about 200 bp and 100 bp
upstream of the translational start site respectively. ICAM-1
promoter region also contain many AP-1 site in the pro-
moter for its expression via MAP kinase pathways, (through
extracellular signal-regulated kinase (ERK), the c-Jun amino-
terminal kinase (JNK), and the p38 kinase) important for
ICAM-1 expression in endothelial cells. The ICAM-1 variants
are present in introns, exons and promoter region. It is well
known that intronic variants have the potential to effect a
change inmRNA (messenger Ribonucleic Acid) processing andstability that can result in aberrant splicing16 causing altered
cellecell interaction.
ICAM-2 gene is located on chromosome 17 region q23-25,
codes for a family of type I cell surface glycoprotein which
are characterized by immunoglobulin-like extracellular C-
type domains that vary in number between two and nine
(ICAMe2, -4 have two, and ICAM-1, -3 have five, ICAM-5 have
nine domains) followed by a transmembrane region and a
cytoplasmic domain. The cell-surface ligands are integrin
lymphocyte function-associated antigen-1 LFA-1 (CD18/
CD11a, L2), and (ICAM-1, -2, and -4) integrin Mac-1 (macro-
phage antigen-1) (CD18/CD11b, M2) and (ICAM-3) novel
integrin CD18/CD11d, D2.17
Leukocytes, endothelial cells and platelets express ICAM-2
(CD102) constitutively but the expression remains at basal
levels by inflammatory cytokines or other treatments under
all conditions studies.18
ICAM-3(CD 50) also constitutively expressed highly on the
surface of almost resting leucocytes (neutrophils, monocytes,
and lymphocytes whereas endothelium ICAM-3 expression is
low in inflammatory diseases. It may be important in the
generation of immune responses.19 Red Blood.
Cell (RBC) specifically expresses ICAM-4 whereas ICAM-5
(telencephalin, TLN) is expressed only by neurons within the
telencephalon of mammalian brains. Platelet or endothelial
cell adhesion molecule-1 PECAM-1 (CD31 antigen) mapped to
chromosome 17 in the region 17q23 is expressed on the sur-
face of circulating platelets, monocytes, neutrophils, and
particular T cell subsets are implicated in transendothelial
migration of leukocytes, angiogenesis, and integrin activation.
Mononuclear cell-specific adhesionmolecule VCAM-1 (CD106)
mapped to 1p32-p31 was found only on the surface of
mononuclear cells and not on normal endothelium at base-
line. Macrophages and dendritic cells, its counter receptor is
the integrin very late antigen-4 (VLA-4, CD49d/CD29 and a4b1)
is expressed onmonocytes, lymphocytes, and eosinophils, but
not on neutrophils. Interaction between VLA-4 and VCAM-1
plays major role in binding of this cell to activated endothe-
lial cells.3. ICAM-1
The ICAM-1 exists as membrane bound and soluble (sICAM-1)
glycoprotein. Membrane bound protein belongs to type 1
transmembrane with molecular weight varies on glycosyla-
tion pattern (unglycosylated 60 KDa and glycosylated
80e114 KDa). It was demonstrated to be expressed also in
leukocytes and endothelial cells (EC). This protein has extra-
cellular portion (attached to a 24 residues single hydrophobic
transmembrane region), transmembrane and a 28 residues
short cytoplasmic tail. Five extracellular domains (D-1 to D-5)
contain 453 amino acids, mostly hydrophobic and its b-sheet
structure is stabilized by di-sulfide bond.20 The D1 and D3
interact with their ligands LAF-1 and Mac-1 on leukocytes
correspondingly and the tyrosine residue of cytoplasmic tail
mediates the signaling pathway. Trans-endothelial migration
of leukocytes to the site of inflammation occurs in four steps
through rolling and leukocyte integrin tethering attachment
(Endothelial E-and P-selectin binding), activation of integrins
Fig. 1 e Normal vascular lumen with intact endothelium.
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(LFA-1, Mac-1) and leukocyte migration into sub-endothelial
surface. ICAM-1 causes leukocyte transmigration by EC junc-
tional adhesion molecules weakening and contraction via
inducing intracellular Ca2þ levels leading to the activation of
p38 and Rho.21
Like membrane bound ICAM-1, it possess extracellular
domain except transmembrane and cytoplasmic region.
sICAM-1 is expressed on the wide variety of human cells such
as vascular EC, saphenous vein EC, aortic smooth muscle cell,
astrocytes, keratinocytes and carcinoma cells. It released in to
circulation through the proteolytic cleavage of extracellular
region of membrane bound ICAM-1 by Matrix Metal-
loproteinases (MMP), human leukocyte elastase and TNF-a
converting enzyme (TACE)22 and its level may be detected in
blood and other body fluids. The advantages of sICAM-1
binding with its ligands have been suggested explored to uti-
lize it as a potential agent to block interaction of leukocyte and
endothelial.23 Recent studies suggested that circulating serum
sICAM-1 concentration can be used predict the risk of post
transplant ischemic events or cardiac graft failure and CAD.244. ICAM-1 and its molecular pathogenesis
mechanism
The interaction between lipids, the endothelium, circulating
and tissue inflammatory cells (leukocytes), platelets and
vascular smooth muscle cells and extracellular matrix in the
intima of large arteries results in pathogenesis of disease, are
one of the earliest and critical events. In case of atheroscle-
rosis, hyperlipidemia causes slowing down of circulating
leukocytes in the streaming blood by rolling and tethering of
circulating leukocytes in the monocytes and lymphocytes
along the arterial endothelial lining, mediated by the selectin
class of adhesion molecules and subsequent firm attachment
to endothelial cells and transendothelial migration of these
adherent leukocytes across the endothelial surface to the in-
tima of the blood vessels wall. Its accumulation in the intima
is mediated by b2-integrins by interacting with counter li-
gands from the Ig superfamily including the ICAM-1 in acti-
vated endothelial cells, where monocytes transform into lipid
engorged “foam cells” by the uptake of lipids that which re-
sults of fatty streak lesions formation. The secretion of cyto-
kines and growth factors are also important events in the
initiation and progression of atherosclerotic plaques25 as
shown in Fig. 2 incontrast to normal endothelium as shown in
Fig. 1.5. Discussion
ICAM-1 is a well-known identified critical molecule secreted
by endothelium during vascular inflammation and is
responsible for formation, growth and rupture of atheroma.26
Table 1 provides the ICAM-1 gene SNP's details that are
investigated for its clinical association with cardiac diseases.
Among the SNP's, G241R and K469E gene are studied in quite
considerable number of population globally and are impli-
cated for different phenotypes. The studies of McGlinchey PGet al27 (2004), Milutinovic A et al28 (2006) and Aminian B et al
(2007)1 showed the lack of ICAM-1 gene association with
Ischemic Heart Disease (IHD) (K469E) and MI (G24R1) patients.
In contrast, a recent study29 on atherosclerosis risk commu-
nities concluded that ICAM-1 241RR genotype is associated
with increased risk of incident Ischemic Stroke (IS) in both
whites and African Americans. The same study also demon-
strated the non-association of K469Egenotype. Mohammed
AA et al30 proved that K469E polymorphism is positively
associated with CAD and negatively associated with the
circulating levels of sICAm-1 in Egyptian population. For ACS
recurrence and cardiacmortality, Liu Lz et al31 proposed that K
allele could be independent risk factor. In 2014, Zou S32 et al
performed a control studymeta-analysis on large Chinese and
established that individuals with KK genotype carries CAD
risk by 80% in similar to Lid et al,33 Jin Yn et al34 and Yanan Y
et al.35 Clinical studies also suggested that ICAM-1 genotypes
were not related to CAD severity,36 intima medial thickness
and coronary artery calcium.11
Classical risk factors such DM, HTN, hyperlipidemia and
smoking parameters, either alone or in combination provides
invaluable information in predicting the risk of CAD due to the
disease complexity. Hence, the search for biomarkers to
validate risk factor was necessitated. Studies attaining this
objective have shown the synergistic effect of rs5498 poly-
morphisms with smoking and triglycerides (G allele) posess
threats to CAD64 risk like other risk factors such DM2 (AA ge-
notype: K469E), HTN and low HDL concentration.65 GWA
investigation studied four novel loci and showed that ICAM-1
(K469E) polymorphism determines the circulating concentra-
tion of sICAM-166 apart from G241R.
Circulating levels of sICAM-1 showed positive and negative
associations30 with atherosclerosis particularly with CAD and
unstable angina patients. Studies67 were carried to determine
whether polymorphism affects the sICAM-1 levels or cell
cellecell binding ability. It concluded that G241R/K469E poly-
morphisms are responsible for expression pattern and not
Fig. 2 e Schematic detailed representation of ICAm-1 molecular mechanism for CAD and MI; LPS Lipopolysachride, TNF
Tumor Necrosis Factor, ROS Reactive Oxygen Species, LDL Low Density Lipoproteins.
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that sICAM-1 may be used to predict post operative LCO
event68 in pulmonary artery hypertensive patients, MI prog-
ress and recurrence after thrombolysis.69 It was also found to
have inverse relation with left ventricular ejection fraction.70
Clinical studies have shown that pitavastatin stimulated
urocortin-1,71 belongs to corticotrophin releasing factor/Uro-
tensin I family to be safe and effective anti-inflammatory and
may be used as a new line of atherosclerosis related diseases
treatment in future.
The results of genotypes are still debatable except in Chi-
nese population than the rest of theworld, as the publication's
and sample size are less. Even the limited number of publi-
cation doesn't permit us for meta-analysis of data in that
particular region. This might be attributable to high cost
involved in genotyping techniques such Polymerase ChainTable 1 e ICAM-1 molecule SNP's information.
S. No SNP Allele change Amino ac
2 rs5491 A > T Lys56Met (M56
1 rs1799969 G > A Gly241Arg (G24
4 rs1801714 C > T Pro352Leu (P35
3 rs5498 A > G Lys469Glu (K46
5 rs 281428 C > T
6 rs281432 C > G
7 rs281437 C > TReaction-Fragment Length Polymorphism (PCR-RFLP),30
sequencing or real time RCR29 which are commonly
employed by the researchers. Hence, we suggest the use of
reliable, convenient and less time consuming novel genotyp-
ing method of Polymerase Chain Reaction with Confronting
Two Pair Primer (PCR-CTPP).72 This method involves normal
PCR reaction with four primers (a pair forward and reverse
primer) followed by agarose gel electrophoresis and has been
demonstrated in clinical samples.73 The designing of primers
could be done using prim-SNPing online software tool.
In general beyond ethnicity, ICAM-1 K469 E and G241R
genotype is found to be common variant in the diseased
population and may be promising molecule particularly for
clinical and sub-clinical atherosclerosis. Thus, we conclude
that future studies should focus on adopting reliable, cost
effective and less time consuming methods to perform K469Eid change Function Region
K) Missense Exon2
1R) Missense Exon4
2L) Coding non-synonymous Exon5
9E) in domain5 Missense upstream variant Exon 6
e Introns variant Introns
e Intron variant Intron
e Upstream variant (30-UTR) Intron
i n d i a n h e a r t j o u r n a l 6 7 ( 2 0 1 5 ) 2 8 2e2 8 7286and G241R genotyping on large number of similar ethnic
groups and therebymaking it possible to establish the real fate
of genotype for the benefit of the society.Conflicts of interest
All authors have none to declare.
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